Feb 2 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Statement on Oversight Committee release of documents
* Says before Valeant purchased Nitropress and Isuprel, it commissioned outside
consultants to review the drugs' pricing
* Says consultants concluded that the prices of both drugs did not reflect
their true value to hospitals and patients
* Says "going forward, we expect our growth to be driven more by volume than by
price"
* Heard from hospitals, Congress that prices were too high, and Valeant
responded by offering volume-based discounts of up to 30% for each drug
* Says "we are also making overall changes to how we run our business"
* Says in 2016, "expect to invest approximately $400 million on research and
development, $484 million in expanding manufacturing in Rochester"
* Source text
* Further company coverage VRX.TO